Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13857839 | 0.87 | ALDH1A1 (0.50) | ERBB2ADORA1ADORA2AALDH1A1HPGD | |
| SCHEMBL32688280 | 0.86 | ADORA1 (0.58) | ADORA1ADORA2AALDH1A1HPGDADORA2B | |
| SCHEMBL8402351 | 0.78 | ALDH1A1 (0.49) | ERBB2ADORA1ADORA2AALDH1A1HPGD | |
| SCHEMBL19665238 | 0.77 | ADORA1 (0.69) | ADORA1ADORA2AADORA2B | |
| SCHEMBL1162660 | 0.77 | ALDH1A1 (0.60) | ERBB2ADORA1ADORA2AALDH1A1HPGD | |
| SCHEMBL1162755 | 0.74 | ALDH1A1 (0.51) | ERBB2ADORA1ADORA2AALDH1A1HPGD | |
| SCHEMBL1162824 | 0.74 | ALDH1A1 (0.81) | ERBB2ADORA1ADORA2AALDH1A1HPGD | |
| SCHEMBL13857777 | 0.74 | GPR84 (0.42) | ERBB2ALDH1A1HPGDDHODH | |
| SCHEMBL1163234 | 0.73 | ALDH1A1 (0.52) | ERBB2ADORA1ADORA2AALDH1A1HPGD | |
| SCHEMBL22208277 | 0.73 | ADORA1 (0.66) | ADORA1ADORA2AALDH1A1HPGDADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464647-B1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2464647-B1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2016-09-21 | — | — | EP | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2464647-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| WO-2011019780-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BTK, ABL1, JAK1 | ERBB2 23/4885ADORA1 706/4885ADORA2A 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.